Hepalink 2025 Profit Falls on API Weakness Despite Modest Revenue Growth

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) has shared an update.

Shenzhen Hepalink Pharmaceutical Group reported 2025 revenue of RMB5.44 billion, up slightly from a year earlier, with growth driven mainly by its finished dose pharmaceutical products business, whose sales rose to RMB3.50 billion and achieved a higher gross margin. However, group gross profit slipped to RMB1.68 billion and the overall gross margin narrowed as the active pharmaceutical ingredients segment suffered a sharp revenue decline and margin compression, while CDMO sales were flat but somewhat more profitable.

Net profit attributable to shareholders dropped to RMB349.5 million as other income fell sharply and impairment losses and operating expenses weighed on earnings, though finance costs decreased and associates swung to a small gain. The board proposed a lower final cash dividend of RMB1.45 per ten shares, implying a higher payout ratio, signaling continued shareholder returns despite profit pressure and underscoring a strategic tilt toward finished dose products and CDMO to offset weakness in APIs.

The most recent analyst rating on (HK:9989) stock is a Buy with a HK$6.50 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.

More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a China-based pharmaceutical company focused on finished dosage drugs, active pharmaceutical ingredients and contract development and manufacturing (CDMO) services. The group targets both domestic and international markets, with a portfolio spanning injectable therapies and heparin-related products across multiple therapeutic areas.

Average Trading Volume: 861,789

Technical Sentiment Signal: Sell

Current Market Cap: HK$16.8B

Learn more about 9989 stock on TipRanks’ Stock Analysis page.